Biocon Biologics, under the umbrella of Biocon, has been honored yet again as an Asia IP Elite for the year 2024 by Intellectual Asset Management (IAM), a prominent authority on intellectual property. This recognition marks the eighth year running that Biocon and its subsidiary have been included on this esteemed list.
This distinction is reserved for a select cohort of organizations from Asia that excel in creating significant intellectual property value and are acknowledged as trailblazers within the sector. In 2016, Biocon proudly became the first Indian pharmaceutical company to earn a spot on the distinguished Asia IP ELITE list, applauded for its robust IP management and consistent value creation through intellectual property. Biocon Biologics stands as one of only two Indian pharmaceutical companies among the 93 entities listed in the Asia IP Elite 2024 roster.
Shreehas Tambe, CEO and Managing Director of Biocon Biologics, expressed, “Our team’s unwavering commitment to embedding IP into the core of our business continues to drive value generation and enhance healthcare outcomes for millions across the globe.”
Biocon Biologics capitalizes on its strong internal IP approach and capabilities to facilitate the timely introduction of biosimilar products, catering to the demand for affordable treatments in international markets. Each year, IAM undertakes a comprehensive research endeavor, blending both quantitative and qualitative methodologies, to spotlight a select group of leading businesses and research bodies welcomed into the Asia IP Elite.
Members of the Asia IP Elite embody outstanding performance in IP value creation and meet the prerequisites of positioning IP strategy as integral to their business operations. These organizations extract considerable and sustained value from intellectual property due to their strategic initiatives.
Their senior leadership comprehends the pivotal role intellectual property plays in both operational and strategic frameworks. Continuous assessment and enhancement of their IP strategies ensure they are primed to leverage market trends. The Asia IP Elite 2024 includes 93 enterprises from countries such as India, China, Japan, South Korea, Malaysia, Thailand, Taiwan, Australia, New Zealand, and Singapore.